# To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

> **NCT02601703** · PHASE3 · COMPLETED · sponsor: **Glenmark Pharmaceuticals Ltd. India** · enrollment: 1110 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Tacrolimus Ointment 0.1%
- **DRUG:** Protopic® ointment, 0.1%
- **DRUG:** Placebo of Tacrolimus Ointment

## Key facts

- **NCT ID:** NCT02601703
- **Lead sponsor:** Glenmark Pharmaceuticals Ltd. India
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 1110 (ACTUAL)
- **Last updated:** 2019-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02601703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02601703, "To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02601703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*